Immunotherapy for the Post-Infectious Sequela of SARS-CoV-2 Infection
Open Access
- 1 January 2020
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in World Journal of Neuroscience
- Vol. 10 (02), 117-120
- https://doi.org/10.4236/wjns.2020.102013
Abstract
The SARS-CoV-2 2019 pandemic is creating challenges to the management of post-infectious autoimmunity in childhood and adult Covid-19 cases due to its high case fatality. Nearly all of the agents envisioned to treat Covid-19 illness, including the newly recognized pediatric multi-system inflammatory syndrome, impact post-infectious mechanisms in keeping with the multiplier effect of infection, immunity and inflammation, known as I-Cubed (I3).Keywords
This publication has 9 references indexed in Scilit:
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19The New England Journal of Medicine, 2020
- Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemicThe Journal of Pediatrics, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019Open Forum Infectious Diseases, 2020
- New fronts emerge in the influenza cytokine stormSeminars in Immunopathology, 2017
- I-Cubed (Infection, Immunity, and Inflammation) and the Human MicrobiomeNeurologic Clinics, 2016
- Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral ActivitiesJournal of Medicinal Chemistry, 2006